MedPath

Study of Metformin Pharmacogenetics in Twins

Phase 1
Completed
Conditions
Type 2 Diabetes
Interventions
Registration Number
NCT01869621
Lead Sponsor
University of Southern Denmark
Brief Summary

The trough concentration of metformin will be examined in monozygotic and dizygotic twins. Current twin study will determine the total weight of genetics on the trough concentration of metformin.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
34
Inclusion Criteria
  • Age 18-40 years
  • Both twins has to be included
  • Dizygotic twin pairs has to be same sex
  • Informed consent given
  • Healthy condition
Exclusion Criteria
  • Chronical/daily alcohol abuse
  • Hypersensitivity to metformin
  • Ingestion of drugs containing topiramate or x-ray contrast fluids
  • For women: Positive pregnancy test/breastfeeding at the beginning of the trial. No use of safe anticonceptives

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
MetforminMetformin6 days treatment with metformin
Primary Outcome Measures
NameTimeMethod
HeritabilityAfter 6 days of metformin treatment

The trough concentrations of metformin in twin pairs will be used to determine the effect of heritability on metformin trough concentrations. This will give insight to the weight that genetic factors have on metformin pharmacokinetics at steady-state.

Secondary Outcome Measures
NameTimeMethod
Single nucleotide polymorphisms (SNPs)After 6 days treatment with metformin

The effect of SNPs on trough metformin concentration

Trial Locations

Locations (1)

Clinical Pharmacology

🇩🇰

Odense C, Denmark

© Copyright 2025. All Rights Reserved by MedPath